Since the abundance of RNF183-targeted shRNA was significantly decreased in the trametinib group (P < 0.05) (Fig. 1b), and since it has been reported to play an important role in inflammatory bowel disease [16], which is a causative factor of CRC, we selected this gene for further experiments. Here, RNF183 is linked to colorectal carcinoma.